Gepirone ER - Fabre-Kramer Pharmaceuticals

Drug Profile

Gepirone ER - Fabre-Kramer Pharmaceuticals

Alternative Names: BMY 13805; MJ 13805; Org 33062; TGFK07AD; Travivo; Variza™

Latest Information Update: 11 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Fabre-Kramer Pharmaceuticals
  • Class Antidepressants; Anxiolytics; Hypnosedatives; Pyrimidines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Major depressive disorder

Most Recent Events

  • 03 Jan 2018 Fabre-Kramer Pharmaceuticals and Mission Pharmacal enter into a manufacturing agreement for the registration batches of Gepirone ER
  • 03 Jan 2018 Fabre-Kramer Pharmaceuticals plans to submit the NDA amendment for Gepirone ER to the US FDA for review and approval in second half of 2018.
  • 21 Sep 2017 Gepirone ER is still preregistered for Major depressive disorder in USA (Fabre-Kramer Pharmaceuticals pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top